All Outputs (10)

Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study (2023)
Journal Article
Atallah, E., Welsh, S. J., O'Carrigan, B., Oshaughnessy, A., Dolapo, I., Kerr, A. S., …Aithal, G. P. (2023). Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study. JHEP Reports, 5(10), Article 100851. https://doi.org/10.1016/j.jhepr.2023.100851

Background & Aims: Checkpoint inhibitors (CPI) account for increasing numbers of drug-induced liver injury (DILI) cases. We aimed to determine the incidence rate and risk factors associated with checkpoint inhibitor-induced liver injury (ChILI). Meth... Read More about Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study.

Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023)
Journal Article
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., …Björnsson, E. S. (2023). Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report. Journal of Hepatology, https://doi.org/10.1016/j.jhep.2023.04.033

Drug-induced liver injury (DILI) can mimic almost all other liver disorders. A phenotype increasingly ascribed to drugs is autoimmune-like hepatitis (ALH). This article summarises the major topics discussed at a joint International Conference held be... Read More about Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.

Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans (2023)
Journal Article
Ravindra, K. C., Vaidya, V. S., Wang, Z., Federspiel, J. D., Virgen-Slane, R., Everley, R. A., …Ramaiah, S. K. (2023). Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans. Nature Communications, 14, Article 1215. https://doi.org/10.1038/s41467-023-36858-6

Diagnosis of drug-induced liver injury (DILI) and its distinction from other liver diseases are significant challenges in drug development and clinical practice. Here, we identify, confirm, and replicate the biomarker performance characteristics of c... Read More about Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans.

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated (2023)
Journal Article
Atallah, E., Grove, J., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., …Aithal, G. (2023). Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology, 78(5), 989-997. https://doi.org/10.1016/j.jhep.2022.12.034

Background & Aims The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-re... Read More about Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated (2023)
Journal Article
Atallah, E., Grove, J. I., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., …Aithal, G. P. (2023). Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology, 78(5), 989-997. https://doi.org/10.1016/j.jhep.2022.12.034

Background & Aims: The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-re... Read More about Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.

Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review (2022)
Journal Article
Niu, H., Atallah, E., Alvarez-Alvarez, I., Medina-Caliz, I., Aithal, G. P., Arikan, C., …Lucena, M. I. (2022). Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review. Drug Safety, 45, 1329-1348. https://doi.org/10.1007/s40264-022-01224-w

Introduction Drug-induced liver injury (DILI) is a rare but serious adverse event that can progress to acute liver failure (ALF). The evidence for treatment of DILI in children is scarce. Objective We aimed to comprehensively review the availabl... Read More about Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review.

A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry (2022)
Journal Article
Björnsson, E. S., Stephens, C., Atallah, E., Alvarez-Alvarez, I., Robles-Diaz, M., Gerbes, A., …Aithal, G. P. (2022). A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry. Liver International, 43(1), 115-126. https://doi.org/10.1111/liv.15378

Background & Aims: No multi-national prospective study of drug-induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short-term outcomes of the cases and controls is reported.... Read More about A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.

Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review (2021)
Journal Article
Atallah, E., Freixo, C., Alvarez-Alvarez, I., Cubero, F. J., Gerbes, A. L., Kullak-Ublick, G. A., & Aithal, G. P. (2021). Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review. Expert Opinion on Drug Metabolism and Toxicology, 17(11), 1327-1343. https://doi.org/10.1080/17425255.2021.1999410

Introduction: Idiosyncratic drug-induced liver injury (DILI) is an unpredictable event, and there are no specific biomarkers that can distinguish DILI from alternative explanations or predict its clinical outcomes. Areas covered: This systematic revi... Read More about Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review.

Zanubrutinib-induced liver injury: a case report and literature review (2021)
Journal Article
Atallah, E., Wijayasiri, P., Cianci, N., Abdullah, K., Mukherjee, A., & Aithal, G. P. (2021). Zanubrutinib-induced liver injury: a case report and literature review. BMC Gastroenterology, 21(1), Article 244. https://doi.org/10.1186/s12876-021-01825-2

Background: Zanubrutinib is a Bruton’s tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of... Read More about Zanubrutinib-induced liver injury: a case report and literature review.

Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study (2020)
Journal Article
White, J. R., Din, S., Ingram, R. J. M., Foley, S., Alam, M. A., Robinson, R., …Moran, G. W. (2020). Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study. Scandinavian Journal of Gastroenterology, 55(8), 907-916. https://doi.org/10.1080/00365521.2020.1790647

Purpose Clinical trials have demonstrated efficacy of vedolizumab in ulcerative colitis (UC) and Crohn’s disease (CD). Further real-world data is needed to inform clinical practice. The primary outcome was to assess corticosteroid-free and clinical... Read More about Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study.